C. diff Risk


Oral Bioavailability


Spectrum Of Activity


2g IV q8h for severe infections

0 - 10 eGFR10 - 50 eGFR50+ eGFR2g IV q24h3-4g IV daily divided q8-12h2g IV q8h

0.5-2g IV load then 500mg IV q12h

2g IV load then 1g IV q6h

General Information

Drug Monitoring

Monitor liver enzymes

Adverse Effects

Elevated liver enzymes, cytopenias, eosinophilia, phlebitis at injection site, rash/allergy, CNS toxicity

Major Interactions

No significant


Antimicrobial class: Monobactam

Pregnancy category: B

Average serum half life: 2.0

Biliary penetration: Moderate

Lung penetration: Therapeutic

Urine penetration: Therapeutic

Common Usage

Therapy of gram negative infections including Pseudomonas, particularly in patients with penicillin and cephalosporin allergy or when there is no alternative susceptible agent

Nebulized form used in cystic fibrosis patients

Empiric therapy for febrile neutropenia